BTIG Reiterates Buy Rating on Monopar Therapeutics Inc. (MNPR)
BTIG maintains its buy rating for Monopar Therapeutics Inc., setting a $117 price target, a 26.36% upside from the current price.
Key Points
- BTIG reiterated its buy rating for Monopar Therapeutics Inc. (MNPR) on June 30, 2026, with a price target of $117.
- BTIG's $117 price target implies 26.36% upside from Monopar Therapeutics Inc.'s ($MNPR) current $92.59 share price.
- Shares of Monopar Therapeutics traded near $94.56 on Wednesday, with a market cap of approximately $620 million.
- Monopar Therapeutics has a strong buy consensus with a mean target price of $112.62 among 13 analysts.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG analyst Jeet Mukherjee reiterated a buy rating for Monopar Therapeutics Inc. (NasdaqCM: MNPR) on June 30, 2026. The firm set a price target of $117 for the biopharmaceutical company. Monopar's shares traded around $94.56 on Wednesday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Monopar Therapeutics
Several institutional investors have shown varied interest in Monopar Therapeutics. Saturn V Capital Management LP increased its holdings by 19,925 shares, reaching a total of 345,626 shares valued at about $18.9 million, marking a 6.1% increase. Deerfield Management Company, L.P. added 153,187 shares, boosting its stake by 89.8% to 323,745 shares worth approximately $17.7 million. Meanwhile, BlackRock, Inc. raised its position by 61,710 shares, a 24.2% increase, resulting in 316,567 shares valued at $17.3 million. In contrast, Adage Capital Partners GP, L.L.C. reduced its stake by 330,272 shares, a 51.6% decrease, ending with 309,195 shares worth about $16.9 million.
Monopar Therapeutics Inc. Stock Down 17.2%
As of Wednesday, shares of Monopar Therapeutics Inc. (NasdaqCM: MNPR) traded near $94.56. The company has a market capitalization of roughly $620 million. Monopar's stock has experienced a 52-week range between $29.18 and $105.00. The stock's 50-day moving average is $62.52, and the 200-day moving average is $67.90. Monopar has a beta of 1.539, indicating a higher volatility compared to the market.
$MNPR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 30, 2026, BTIG maintained its buy rating for Monopar Therapeutics with a $117 price target. The day before, HC Wainwright & Co. reiterated its buy rating with a target of $105. Overall, the consensus among analysts is a strong buy, with a mean price target of $112.62 based on 13 analyst opinions.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Wilmette, Illinois. It focuses on developing cancer treatments, including ALXN1840, a potential therapy for Wilson disease, and MNPR-101, a monoclonal antibody for advanced tumors. Founded in 2014, Monopar collaborates with various partners to advance its pipeline. The company is led by Dr. Chandler D. Robinson and employs 22 people.
Bottom Line
BTIG's reiteration of a buy rating for Monopar Therapeutics Inc. reflects continued confidence in the company's prospects. Investors closely watch such analyst ratings as they provide insights into potential stock performance. As always, it's important to remember that these ratings are based on past data and may not reflect current market conditions.
Get Monopar Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $MNPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.